92 related articles for article (PubMed ID: 18800818)
1. An RGD-modified endostatin-derived synthetic peptide shows antitumor activity in vivo.
Xu HM; Yin R; Chen L; Siraj S; Huang X; Wang M; Fang H; Wang Y
Bioconjug Chem; 2008 Oct; 19(10):1980-6. PubMed ID: 18800818
[TBL] [Abstract][Full Text] [Related]
2. Effect of RGD-4C position is more important than disulfide bonds on antiangiogenic activity of RGD-4C modified endostatin derived synthetic polypeptide.
Yin R; Zheng H; Xi T; Xu HM
Bioconjug Chem; 2010 Jul; 21(7):1142-7. PubMed ID: 20515045
[TBL] [Abstract][Full Text] [Related]
3. RGD-modified endostatin fragments showed an antitumor effect through antiangiogenesis.
Pu CY; Xu HM; Hu JL; Zheng H; Huang XF; Zhang C; Yang YJ; Li YB
Anticancer Drugs; 2012 Sep; 23(8):788-802. PubMed ID: 22555196
[TBL] [Abstract][Full Text] [Related]
4. Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.
Jiang WG; Lu XA; Shang BY; Fu Y; Zhang SH; Zhou D; Li L; Li Y; Luo Y; Zhen YS
BMC Cancer; 2013 Oct; 13():479. PubMed ID: 24128285
[TBL] [Abstract][Full Text] [Related]
5. In vivo pharmacokinetics, immunogenicity and mechanism of PEGylated antitumor polypeptide.
Liu Z; Li W; Xu HM; Huang X; Pan L; Ren Y; Yang Y; Li Y; Pu C; Zhang C
Curr Pharm Des; 2012; 18(12):1655-62. PubMed ID: 22283767
[TBL] [Abstract][Full Text] [Related]
6. A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity.
Tjin Tham Sjin RM; Satchi-Fainaro R; Birsner AE; Ramanujam VM; Folkman J; Javaherian K
Cancer Res; 2005 May; 65(9):3656-63. PubMed ID: 15867360
[TBL] [Abstract][Full Text] [Related]
7. Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth.
Yokoyama Y; Ramakrishnan S
Int J Cancer; 2004 Oct; 111(6):839-48. PubMed ID: 15300795
[TBL] [Abstract][Full Text] [Related]
8. Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization.
Bai Y; Zhao M; Zhang C; Li S; Qi Y; Wang B; Huang L; Li X
PLoS One; 2014; 9(11):e112448. PubMed ID: 25380141
[TBL] [Abstract][Full Text] [Related]
9. A tumor-penetrating peptide modification enhances the antitumor activity of endostatin in vivo.
Hai-Tao Z; Hui-Cheng L; Zheng-Wu L; Chang-Hong G
Anticancer Drugs; 2011 Jun; 22(5):409-15. PubMed ID: 21427563
[TBL] [Abstract][Full Text] [Related]
10. The antiangiogenic and antitumor activities of the N-terminal fragment of endostatin augmented by Ile/Arg substitution: The overall structure implicated the biological activity.
Chamani R; Asghari SM; Alizadeh AM; Mansouri K; Doroudi T; Kolivand PH; Ghafouri H; Ehtesham S; Rabouti H; Mehrnejad F
Biochim Biophys Acta; 2016 Dec; 1864(12):1765-1774. PubMed ID: 27693049
[TBL] [Abstract][Full Text] [Related]
11. RGD-modified endostatin peptide 30 derived from endostatin suppresses invasion and migration of HepG2 cells through the αvβ3 pathway.
Li S; Wei J; Yuan L; Sun H; Liu Y; Zhang Y; Li J; Liu X
Cancer Biother Radiopharm; 2011 Oct; 26(5):529-38. PubMed ID: 21834652
[TBL] [Abstract][Full Text] [Related]
12. Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model.
Becker CM; Sampson DA; Short SM; Javaherian K; Folkman J; D'Amato RJ
Fertil Steril; 2006 Jan; 85(1):71-7. PubMed ID: 16412733
[TBL] [Abstract][Full Text] [Related]
13. Engineering of a disulfide loop instead of a Zn binding loop restores the anti-proliferative, anti-angiogenic and anti-tumor activities of the N-terminal fragment of endostatin: Mechanistic and therapeutic insights.
Chamani R; Asghari SM; Alizadeh AM; Eskandari S; Mansouri K; Khodarahmi R; Taghdir M; Heidari Z; Gorji A; Aliakbar A; Ranjbar B; Khajeh K
Vascul Pharmacol; 2015 Sep; 72():73-82. PubMed ID: 26187352
[TBL] [Abstract][Full Text] [Related]
14. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
15. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin.
Morbidelli L; Donnini S; Chillemi F; Giachetti A; Ziche M
Clin Cancer Res; 2003 Nov; 9(14):5358-69. PubMed ID: 14614021
[TBL] [Abstract][Full Text] [Related]
16. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases.
Heljasvaara R; Nyberg P; Luostarinen J; Parikka M; Heikkilä P; Rehn M; Sorsa T; Salo T; Pihlajaniemi T
Exp Cell Res; 2005 Jul; 307(2):292-304. PubMed ID: 15950618
[TBL] [Abstract][Full Text] [Related]
17. The effect of intracellular protein delivery on the anti-tumor activity of recombinant human endostatin.
Lim J; Duong T; Lee G; Seong BL; El-Rifai W; Ruley HE; Jo D
Biomaterials; 2013 Aug; 34(26):6261-71. PubMed ID: 23714245
[TBL] [Abstract][Full Text] [Related]
18. An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells.
Wickström SA; Alitalo K; Keski-Oja J
J Biol Chem; 2004 May; 279(19):20178-85. PubMed ID: 14973128
[TBL] [Abstract][Full Text] [Related]
19. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization.
Olsson AK; Johansson I; Akerud H; Einarsson B; Christofferson R; Sasaki T; Timpl R; Claesson-Welsh L
Cancer Res; 2004 Dec; 64(24):9012-7. PubMed ID: 15604266
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of recombinant human endostatin combined with chemotherapeutics in mice-transplanted tumors.
Zhu LP; Xing J; Wang QX; Kou L; Li C; Hu B; Wu ZW; Wang JJ; Xu GX
Eur J Pharmacol; 2009 Sep; 617(1-3):23-7. PubMed ID: 19615993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
